Alcon stock gets tighter 2026 outlook after Q3 growth

Alcon reported its third-quarter results on Tuesday, November 10, 2026, with sales growth, higher core earnings and a narrower full-year outlook. The company said in its third-quarter results release that sales for the three months ended September 30 rose 5 percent to 2.717 billion US dollars.

Alcon stock traded at 63.23 euros on Lang & Schwarz at 10:44 CET on Wednesday, November 11, 2026.

Sales Growth Across Both Divisions

The Surgical business generated 1.480 billion US dollars, up 4 percent from the year-earlier quarter. Consumables increased 6 percent to 789 million US dollars, while equipment and other sales rose 11 percent to 269 million US dollars. Implantables declined 2 percent to 422 million US dollars as competitive pressure in the United States weighed on intraocular lens sales.

Vision Care sales advanced 6 percent to 1.237 billion US dollars. Contact lenses grew 4 percent to 737 million US dollars, supported by premium product mix and pricing, while ocular health increased 8 percent to 500 million US dollars. Alcon said growth in dry-eye products, including Tryptyr and Systane, helped the division.

Core Margins Improve In Quarter

Reported operating income rose 15 percent to 381 million US dollars, lifting the operating margin to 14.0 percent from 12.8 percent. Core operating income, a non-IFRS measure, increased 13 percent to 591 million US dollars, and core operating margin expanded to 21.8 percent from 20.2 percent.

Reported diluted earnings per share increased to 0.54 US dollars from 0.48 US dollars. Core diluted earnings per share rose 15 percent to 0.91 US dollars from 0.79 US dollars. The core figures exclude items such as amortization, acquisition-related costs and efficiency measures, so they are not directly comparable with IFRS earnings without considering those adjustments.

Guidance Moves To Narrower Range

Alcon now expects 2026 sales growth of about 6 percent on a constant-currency basis, compared with its previous range of 5 to 7 percent. The company narrowed its expected core operating-margin improvement to 100 to 150 basis points from 90 to 190 basis points and reduced the core diluted EPS growth range to 12 to 14 percent from 12 to 15 percent.

Management said year-to-date sales growth remained 6 percent on a constant-currency basis despite competitive pressure in specific areas. Chief Executive David J. Endicott pointed to momentum from newer products, the product pipeline and the recently announced acquisition of Neurotech Pharmaceuticals, which expands Alcon's retinal-disease portfolio.

One-Off Charges Remain Relevant

For the first nine months, reported sales rose 7 percent to 8.184 billion US dollars, but diluted EPS fell 40 percent to 0.92 US dollars. The decline reflected a 505 million US dollar impairment tied to discontinued PowerVision intraocular-lens programs, alongside efficiency costs and other adjustments. Core diluted EPS for the period increased 14 percent to 2.60 US dollars.

Alcon expanded its efficiency program in November. Total costs are now estimated at approximately 230 million US dollars, while expected annual run-rate savings increased from approximately 100 million to approximately 130 million US dollars. The implementation is expected to be completed in 2026.

The broader Swiss market context is covered in current market reports.

More earnings details and future updates are available in more news and analyses on Alcon stock.